Pentwater Capital Management LP Renalytix PLC Transaction History

Pentwater Capital Management LP

$8.71 Billion
Q4 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.26 - $1.47 $18,200 - $102,900	-70,000 Reduced 10.0%	630,000 $541,000
Q4 2023 Feb 14, 2024	BUY	$0.33 - $1.61 $33,514 - $163,511	101,560 Added 16.97%	700,000 $273,000
Q3 2023 Nov 14, 2023	BUY	$1.51 - $4.01 $50,494 - $134,094	33,440 Added 5.92%	598,440 $957,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $2.92 $130,000 - $189,800	65,000 Added 13.0%	565,000 $1.65 Million
Q1 2023 May 15, 2023	SELL	$1.93 - $3.72 $193,000 - $372,000	-100,000 Reduced 16.67%	500,000 $1.21 Million
Q4 2022 Feb 14, 2023	SELL	$1.06 - $2.21 $123,833 - $258,181	-116,824 Reduced 16.3%	600,000 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$1.19 - $2.78 $555,520 - $1.3 Million	466,824 Added 186.73%	716,824 $918,000
Q2 2022 Aug 15, 2022	BUY	$2.45 - $7.81 $61,250 - $195,250	25,000 Added 11.11%	250,000 $613,000
Q1 2022 May 16, 2022	BUY	$5.88 - $15.9 $363,384 - $982,620	61,800 Added 37.87%	225,000 $1.56 Million
Q4 2021 Feb 11, 2022	BUY	$13.43 - $27.4 $160,327 - $327,101	11,938 Added 7.89%	163,200 $2.6 Million
Q3 2021 Nov 15, 2021	BUY	$17.91 - $34.78 $918,102 - $1.78 Million	51,262 Added 51.26%	151,262 $3.03 Million
Q2 2021 Aug 16, 2021	SELL	$23.56 - $34.25 $412,300 - $599,375	-17,500 Reduced 14.89%	100,000 $3.09 Million
Q1 2021 May 17, 2021	SELL	$15.25 - $31.13 $549,000 - $1.12 Million	-36,000 Reduced 23.45%	117,500 $3.02 Million
Q4 2020 Feb 16, 2021	SELL	$10.69 - $16.0 $277,940 - $416,000	-26,000 Reduced 14.48%	153,500 $2.46 Million
Q3 2020 Nov 16, 2020	BUY	$10.18 - $17.3 $1.83 Million - $3.11 Million	179,500 New	179,500 $2.19 Million

Others Institutions Holding RNLX

# of Institutions

Shares Held

554K

Call Options Held

Put Options Held

View Full List

About Renalytix plc

Ticker RNLX
Exchange OTC
Sector Healthcare
Industry Health Information Services
Shares Outstandng 37,445,900
Market Cap $5.62M
Description
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data ...

More about RNLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Pentwater Capital Management LP with notifications on news.

Account